Testing EGL-001 in patients with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open-label trial that aims to evaluate EGL-001 in patients with advanced or metastatic solid tumors. The study consists of two parts: a Phase 1 dose escalation to determine the optimal dose of EGL-001, administered alone and in combination with anti-PD(L)-1 therapy, followed by a Phase 2 dose expansion at the recommended dose. Approximately 30 to 50 patients will be enrolled across multiple centers in France and Spain. The trial will assess the safety, tolerability, and efficacy of EGL-001 in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed written informed consent
2. Female or male patients, aged at least 18 years
3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
4. Life expectancy of at least 3 months as assessed by the investigator
5. Patients with confirmed locally advanced, unresectable, or metastatic solid tumors who have been previously treated with SoC and are no longer eligible for other therapies
6. Patients who have been treated with an ICI treatment as monotherapy or in combination as SoC
7. Have recovered from previous treatment
8. At least 1 measurable lesion according to RECIST Version 1.1
9. Adequate hematological, hepatic, and renal functions
10. Negative blood pregnancy test at screening for women of childbearing potential
11. Highly effective contraception during the study period and for 6 months after the last study treatment administration for WOCBP, and for male patients who are sexually active with WOCBP. Highly effective contraception methods are defined as:

    * Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectable, implants, intrauterine devices such as Mirena and nonhormonal intrauterine devices such as ParaGard for WOCBP patients or male patients' WOCBP partners
    * Tubal ligation
    * Vasectomy

    In addition to highly effective contraception, participating male patients:
    * Must use a condom during the study period and for 3 months after the last study treatment administration when engaging in any activity that allows for exposure to ejaculate
    * Must refrain from donating sperm
12. Must agree to abstain from donating blood while taking study drug and for 3 months following discontinuation of study treatment
13. Able to understand the character and individual consequences of clinical trial

Exclusion Criteria:

1. Patients with central nervous system metastases and/or leptomeningeal carcinomatosis with some exceptions
2. Patients with active or a documented history of autoimmune disease, immune deficiency or syndrome that required systemic corticoids (except the allowed dose) or immunosuppressive medications
3. Patients who received a previous ICI like anti-PD(L)-1 or an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to toxicity
4. Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs for a period of at least 4 weeks and whose treatment was not stopped 2 weeks prior to the first study treatment, with exceptions. Steroids with no or minimal systemic effect (topical, inhalation) are allowed
5. Patients with history of or current interstitial lung disease or fibrosis, and patients with pneumonitis
6. Other active malignancy requiring active intervention
7. Patients with previous malignancies other than the target malignancy to be investigated in this trial, unless a complete remission was achieved and no additional therapy is required during the study period
8. Patient with any organ transplantation, including allogeneic stem cell transplantation
9. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma
10. Any known allergy or severe reaction to any component of anti-CTLA-4 or anti-PD(L)-1 drug product
11. Significant chronic or acute infections requiring systemic therapy including SARS-CoV-2 (COVID-19) PCR positive testing
12. Clinically significant active cardiovascular disease
13. Any other medical conditions or psychological disorders that would increase the safety risk to the patient or interfere with participation of the patient or the evaluation of the clinical study in the opinion of the investigator
14. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial

Where it's running

• Institut Regional Du Cancer De Montpellier
  Montpellier, France Recruiting
• Institut Curie
  Paris, France Recruiting
• Hospital Clinico Universitario De Valencia
  Valencia, Spain Recruiting
• Centr Georges Francois Leclerc
  Dijon, France Not yet recruiting
• Institut Gustave Roussy
  Paris, France Not yet recruiting
• Hospital Universitari Vall D Hebron
  Barcelona, Spain Not yet recruiting

Study contacts

• Study coordinator: Pejvack Motlagh, MD
• Email: contact@egle-tx.com
• Phone: 33660462343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HMPL-A830 in solid tumors for adults with unresectable or metastatic cancer

  This first-in-human study tests HMPL-A830 in adults with unresectable or metastatic solid tumors to see how safe it is and how it behaves at varying doses.

  Recruiting at 4 sites Phase 1/2 Hutchmed · Orange, California and 13 other locations · NCT07718581

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• DESCANSO/REST mental health program for Spanish-speaking Latino adults with cancer experiencing depression, insomnia, and fatigue

  This program will test whether a telehealth-delivered DESCANSO/REST intervention can help Spanish-speaking Latino adults with stage I–III solid tumors who are receiving systemic cancer treatment feel less depressed, sleep better, and have less fatigue.

  Recruiting at 8 sites Ponce Medical School Foundation, Inc. · Basking Ridge, New Jersey and 7 other locations · NCT07225088

• Personalized PULSAR radiotherapy for advanced small cell lung cancer and brain metastases

  This trial will try personalized PULSAR radiotherapy schedules to see if they are safe and helpful for adults with extensive-stage small cell lung cancer who need thoracic radiation and for adults with 1–5 brain metastases.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07139990

• VS-7375 for adults with KRAS G12D-mutated advanced solid tumors.

  This trial tests VS-7375, alone and combined with other cancer drugs, in adults with unresectable or metastatic solid tumors that have the KRAS G12D mutation.

  Recruiting at 22 sites Phase 1/2 Verastem, Inc. · Los Angeles, California and 21 other locations · NCT07020221

• Using a modified cold virus to treat certain solid tumors

  This study is testing a new treatment made from a modified cold virus to see if it can safely target and help people with certain types of solid tumors.

  Recruiting at 7 sites Phase 1/2 Accession Therapeutics Limited · Barcelona and 7 other locations · NCT06977737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.